50 of the best-funded biotechs of 2023

[Adobe Stock]

As the year draws to a close, it is clear that molecular science and diagnostics is the hottest funding area in the biotech industry. In an analysis of 50 of the best-funded biotechs of 2023 focused on human health, molecular and science and diagnostics startups collectively attracting roughly $945 million, dwarfing the figures in other segments. The next popular two niches, gene therapies and oncology, had average funding levels of approximately $245 million and $170 million, respectively. While AI has received a significant amount of attention this year, biotechs specializing in that field garnered an average funding of only about $66 million. Outside of the life sciences, startups with a broader focus on AI raised a cumulative average of $202.47 million, based on an analysis of close to 1000 companies.

Caris Life Sciences has raised nearly $1.7B to date

In terms of best-funded companies overall,…

Read more
  • 0

Janssen exec discusses company’s precision neuroscience strategy and partnerships

[Aliaksandr Marko/Adobe Stock]

In mid-April, San Diego–based Pipeline Therapeutics announced a global license and development agreement with Janssen Pharmaceutica NV (NYSE:JNJ), focusing on PIPE-307, an investigational compound targeting nervous system disorders. As a pioneer in precision neuroscience, Pipeline Therapeutics aims to create targeted treatments for patients. PIPE-307, an oral, highly selective antagonist of the muscarinic M1 receptor, embodies this approach, having completed two phase 1 clinical trials and obtained FDA clearance for clinical development in relapsing-remitting multiple sclerosis (RRMS) patients. Janssen received a worldwide, exclusive license to research and develop PIPE-307 in all indications.

Under the agreement, Pipeline will receive $50 million upfront from Janssen, with the possibility of receiving an additional $25 million in equity investments from J&J and Pipeline’…

Read more
  • 0